Holen Sie sich die Stockscreener-App
2.93
2.45%
0.07
Handel nachbörslich:
2.86
-0.07
-2.39%
Schlusskurs vom Vortag:
$2.86
Offen:
$2.88
24-Stunden-Volumen:
195.15K
Relative Volume:
0.14
Marktkapitalisierung:
$23.65M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.60M
KGV:
-3.2921
EPS:
-0.89
Netto-Cashflow:
$-23.48M
1W Leistung:
+0.00%
1M Leistung:
-15.56%
6M Leistung:
-66.32%
1J Leistung:
-80.66%
1-Tages-Spanne:
$2.8761
$3.11
1-Wochen-Bereich:
$2.85
$3.14
52-Wochen-Spanne:
$2.78
$29.40
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Firmenname
Briacell Therapeutics Corp
Sektor
Branche
Telefon
(604) 921-1810
Adresse
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Vergleichen Sie BCTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCTX
Briacell Therapeutics Corp
|
2.93 | 23.65M | 0 | -16.60M | -23.48M | -0.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-02-14 | Eingeleitet | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Aktie (BCTX) Neueste Nachrichten
BriaCell Reports Increased Losses in Latest Financials - TipRanks
(BCT) Advanced Trading Insights (BCT:CA) - news.stocktradersdaily.com
Briacell Therapeutics Corp expected to post a loss of $1.76 a shareEarnings Preview - TradingView
Learn to Evaluate (BCT) using the Charts (BCT:CA) - news.stocktradersdaily.com
(BCT) Strategic Equity Report (BCT:CA) - news.stocktradersdaily.com
(BCT) Investment Analysis and Advice (BCT:CA) - news.stocktradersdaily.com
BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26 - GlobeNewswire
(BCT) Pivots Trading Plans and Risk Controls (BCT:CA) - news.stocktradersdaily.com
Stocks In Play - Baystreet.ca
Stocks in play: BriaCell Therapeutics Corp. - The Globe and Mail
BriaCell Therapeutics Corp. - Baystreet.ca
BriaCell Therapeutics Schedules Virtual Investor Presentations for June 2025 - TipRanks
BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26 | BCTX Stock News - GuruFocus
BriaCell’s Bria-IMT Shows Strong Survival & Benefit in Advanced Breast Cancer - Insider Monkey
Stocks In Play: BriaCell Therapeutics Corp. By Baystreet.ca - Investing.com Canada
Stocks In Play: BriaCell Therapeutics Corp. - Barchart.com
BriaCell Reports Promising Survival Data in Metastatic Breast Cancer Studies - TipRanks
BriaCell (BCTX) Shares Clinical Advancements at ASCO Meeting | B - GuruFocus
BriaCell (BCTX) Shares Clinical Advancements at ASCO Meeting | BCTX Stock News - GuruFocus
BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025 - The Manila Times
Clinical Trial Success: BriaCell's Breast Cancer Treatment Outperforms FDA-Approved Therapies at ASCO 2025 - Stock Titan
(BCT) Stock Market Analysis (BCT:CA) - news.stocktradersdaily.com
(BCT) Market Dynamics and Trading Signals (BCT:CA) - news.stocktradersdaily.com
BriaCell (BCTX): Advances in Cancer Treatment with Bria-OTS | BC - GuruFocus
BriaCell Therapeutics (NASDAQ:BCTX) Stock Price Up 1.6% – Should You Buy? - Defense World
When (BCT) Moves Investors should Listen (BCT:CA) - news.stocktradersdaily.com
BriaCell Therapeutics Corp - Baystreet.ca
Cardiol Therapeutics Inc. - Baystreet.ca
BriaCell advances cancer treatment with Bria-OTS in clinical study By Investing.com - Investing.com South Africa
BriaCell Bria-OTS? Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor - marketscreener.com
BriaCell advances cancer treatment with Bria-OTS in clinical study - Investing.com
BriaCell Advances Bria-OTS in Cancer Immunotherapy with New Study Phase - TipRanks
BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Dos - GuruFocus
BriaCell (BCTX): Advances in Cancer Treatment with Bria-OTS | BCTX Stock News - GuruFocus
BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety - GlobeNewswire
BriaCell's Breast Cancer Immunotherapy Shows Early Success: Patient's Lung Metastasis Completely Resolved - Stock Titan
(BCT) Advanced Equity Analysis (BCT:CA) - news.stocktradersdaily.com
BriaCell Therapeutics: Stocks Undervalued by Analyst Consensus on TSX (BCT) - The Globe and Mail
BriaCell (BCTX) Showcases Promising Data at ASCO 2025 | BCTX Sto - GuruFocus
BriaCell Therapeutics Reports Promising Phase 2 Results for Metastatic Breast Cancer Treatment - TipRanks
BriaCell to Showcase Survival and Clinical Benefit Data at ASCO Meeting Next Week - marketscreener.com
BriaCell (BCTX) Showcases Promising Data at ASCO 2025 | BCTX Stock News - GuruFocus
BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025 - The Manila Times
‘Don’t Doubt UNH Yet,’ Top JPMorgan Analyst Defends UnitedHealth Stock amid Recent Volatility - The Globe and Mail
Breakthrough: BriaCell's New Breast Cancer Drug Shows 13.4-Month Survival Rate, Beating Standard Therapies - Stock Titan
OpenAI CEO Sam Altman Admits Even They Are ‘a Little Bit Scared’ of What They’re Building—But That’s a Good Thing - The Globe and Mail
Stock Market News Today, 5/22/25 – Futures Flat, Post Deficit-Fear-Driven Sell-Off - The Globe and Mail
Moderna Stock Looks Ripe for a Short Squeeze - The Globe and Mail
(BCT) Trading Signals (BCT:CA) - news.stocktradersdaily.com
BriaCell CEO Letter to Shareholders | BCTX Stock News - GuruFocus
BriaCell (BCTX) Reports Promising Advances in Cancer Treatment Studies | BCTX Stock News - GuruFocus
Finanzdaten der Briacell Therapeutics Corp-Aktie (BCTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):